title: Secretoneurin, substance P and neuropeptide Y in the oxygen-induced retinopathy in C57Bl/6N mice.
abstract: In this study, we investigated whether the proangiogenic neuropeptides secretoneurin (SN), substance P (SP), and neuropeptide Y (NPY) contribute to the development of abnormal neovascularization in the oxygen-induced retinopathy (OIR) model in mice. By exposing litters of C57Bl/6N mice to 75% oxygen from postnatal day 7 (P7) until postnatal day 11 (P11) and then returning them to normoxic conditions, retinal ischemia and subsequent neovascularization on the retinal surface were induced. Retinae were dissected on P9, P11, P12-P14, P16 and P20, and the concentrations of SN, SP, NPY and VEGF determined by radioimmunoassay or ELISA. The levels of SN and SP increased in controls from P9 until P16 and from P9 until P14, respectively, whereas the levels of NPY were high at P9 and decreased thereafter until P20, suggesting that NPY may participate in the development of the retina. However, dipeptidyl peptidase IV (DPPIV) and the NPY-Y2 receptor were not detectable in the immature retina indicating that NPY is not involved in the physiological vascularization in the retina. Compared to controls, OIR had no effect on the levels of SN, whereas levels of both SP and NPY slightly decreased during hyperoxia. Normalization of the levels of SP, and to a more pronounced extent of NPY, was significantly delayed during relative hypoxia. This clearly indicates that these three neuropeptides are not involved in the pathogenesis of neovascularization in OIR. Moreover, since there were no differences in the expression of two vessel markers in the retina of NPY knockout mice versus controls at P14, NPY is also not involved in the delayed development of the intermediate and deep vascular plexus in the retina in this animal model.
authors.affiliation: Department of Ophthalmology and Optometry, Innsbruck Medical University, Innsbruck, Austria.
authors.forename: Eduard
authors.initials: E
authors.lastname: Schmid
authors.forename: Marina
authors.initials: M
authors.lastname: Nogalo
authors.forename: Nikolaos E
authors.initials: NE
authors.lastname: Bechrakis
authors.forename: Reiner
authors.initials: R
authors.lastname: Fischer-Colbrie
authors.forename: Ramon
authors.initials: R
authors.lastname: Tasan
authors.forename: Günther
authors.initials: G
authors.lastname: Sperk
authors.forename: Markus
authors.initials: M
authors.lastname: Theurl
authors.forename: Arno G E
authors.initials: AG
authors.lastname: Beer
authors.forename: Rudolf
authors.initials: R
authors.lastname: Kirchmair
authors.forename: Herbert
authors.initials: H
authors.lastname: Herzog
authors.forename: Josef
authors.initials: J
authors.lastname: Troger
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D018496:Hyperoxia; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009478:Neuropeptide Y / Q000032:analysis* / Q000172:deficiency / Q000378:metabolism*; D009479:Neuropeptides / Q000032:analysis*; D011863:Radioimmunoassay; D012160:Retina / Q000737:chemistry; D015861:Retinal Neovascularization / Q000378:metabolism* / Q000473:pathology*; D053381:Secretogranin II / Q000032:analysis*; D013373:Substance P / Q000032:analysis*
chemical_list: D009478:Neuropeptide Y; D009479:Neuropeptides; D053381:Secretogranin II; C081159:secretoneurin; D013373:Substance P